Skip to main content

LexaGene to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

BEVERLY, MA / ACCESSWIRE / August 17, 2021 / LexaGene Holdings, Inc., (OTCQB:LXXGF)(TSXV:LXG) a molecular diagnostics company developing automated rapid polymerase chain reaction (PCR) testing solutions for veterinary diagnostics and biopharmaceutical manufacturing, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Thursday, August 19, 2021 at 10:30 AM EST. Dr. Jack Regan, CEO and Founder, will be hosting the presentation and answering questions from investors.

To access the live presentation, please use the following information:

SNN Network Summer Virtual Event 2021

Date: Thursday, August 19, 2021

Time: 10:30 AM Eastern Time (7:30 AM Pacific Time)

Webcast: https://www.webcaster4.com/Webcast/Page/2750/42521

"Since launching MiQLab™, we've experienced a tremendous amount of growth and positive momentum resulting from a number of scientific studies that have produced robust data validating our system's efficacy," said Dr. Jack Regan. "As we move ahead with our commercialization strategies, we continue to see great promise in the space of veterinary diagnostics, food safety, and biopharmaceutical manufacturing. We believe, MiQLab will change the way these industries conduct their business, for the better. I'm excited to speak to investors at this year's SNN Network Virtual Event and share our vision for the future of molecular diagnostic testing."

If you would like to book 1on1 investor meetings with Dr. Jack Regan or to watch LexaGene's presentation, please make sure you are registered for the virtual event here: https://conference.snn.network/signup

1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

The SNN Network Summer Virtual Event website is available here: https://conference.snn.network/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://conference.snn.network/agenda

Watch a pre-event interview with SNN CEO Robert Kraft and LexaGene's Dr. Jack Regan, here: https://www.youtube.com/watch?v=sAg2yLEmRAk

To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit www.lexagene.com, or follow us on Twitter or LinkedIn.

About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing, and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go'. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN Network.

If you would like to attend the SNN Network Summer Virtual Event 2021, please register here: https://conference.snn.network/signup

LexaGene Corporate Contact:
Gail Winslow, APR
Director of Corporate Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824

LexaGene Investors:
Sharon Choe
Senior Vice President
LaVoieHealthScience
schoe@lavoiehealthscience.com
(857) 241-7393

SNN Contact:
Robert Kraft
CEO, SNN Incorporated
818-983-5500
rkraft@snnwire.com

News Compliments of Accesswire

SOURCE: LexaGene via SNN Network



View source version on accesswire.com:
https://www.accesswire.com/660032/LexaGeneto-Present-at-the-SNN-Network-Summer-Virtual-Event-on-Thursday-August-19-2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.